What is ALUNBRIG® (brigatinib)?
ALUNBRIG is a once-daily oral prescription medication that helps treat adults with ALK+ metastatic non-small cell lung cancer (NSCLC). Your doctor has recommended a new treatment and you may have questions.
Who Can Be Treated With ALUNBRIG?
ALUNBRIG is approved to treat adults with NSCLC:
- that has an abnormal ALK gene, and
- that has spread to other parts of the body
It is not known if ALUNBRIG is safe and effective in children.
How Does ALUNBRIG Work?
ALUNBRIG is a type of targeted therapy. Targeted therapies can inhibit or slow the disease growth, progression, and spread of cancer by targeting specific molecules that are responsible for cancer cell growth.
- ALUNBRIG is a tyrosine kinase inhibitor, or ALK inhibitor
- ALUNBRIG works by blocking the abnormal ALK protein responsible for the growth and spread of ALK+ non-small cell lung cancer.
Learn More About ALUNBRIG as a First Treatment
Learn More About ALUNBRIG After Another Treatment
It's normal to have questions as you begin your treatment on ALUNBRIG.
We have additional resources for you to discuss with your healthcare provider as you get started.
- ALK gene - A gene that makes a protein called anaplastic lymphoma kinase or ALK, which is involved in cell growth. Mutated or genetically changed forms of the ALK gene and protein have been found in some types of cancer, such as NSCLC.
- Targeted therapy - A type of treatment that can inhibit or slow the disease growth, progression, and spread of cancer by targeting specific molecules that are responsible for cancer cell growth. Some targeted therapies block the action of certain enzymes, proteins, or other molecules involved in the growth and spread of cancer cells.